CN106132960B - 用作蛋白质聚集抑制剂的杂芳基酰胺 - Google Patents

用作蛋白质聚集抑制剂的杂芳基酰胺 Download PDF

Info

Publication number
CN106132960B
CN106132960B CN201580017216.1A CN201580017216A CN106132960B CN 106132960 B CN106132960 B CN 106132960B CN 201580017216 A CN201580017216 A CN 201580017216A CN 106132960 B CN106132960 B CN 106132960B
Authority
CN
China
Prior art keywords
compound
mmol
disease
asyn
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580017216.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106132960A (zh
Inventor
E·M·斯托金
W·赖斯德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Youshibi Biomedical Co Ltd
Original Assignee
Youshibi Biomedical Co ltd
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106132960(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Youshibi Biomedical Co ltd, Neuropore Therapies Inc filed Critical Youshibi Biomedical Co ltd
Priority to CN201911278647.XA priority Critical patent/CN111039939B/zh
Publication of CN106132960A publication Critical patent/CN106132960A/zh
Application granted granted Critical
Publication of CN106132960B publication Critical patent/CN106132960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580017216.1A 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺 Active CN106132960B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911278647.XA CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US61/933,246 2014-01-29
US201462078895P 2014-11-12 2014-11-12
US62/078,895 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911278647.XA Division CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Publications (2)

Publication Number Publication Date
CN106132960A CN106132960A (zh) 2016-11-16
CN106132960B true CN106132960B (zh) 2019-12-17

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580017216.1A Active CN106132960B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺
CN201911278647.XA Active CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911278647.XA Active CN111039939B (zh) 2014-01-29 2015-01-28 用作蛋白质聚集抑制剂的杂芳基酰胺

Country Status (38)

Country Link
US (3) US9738635B2 (https=)
EP (2) EP3348556B1 (https=)
JP (2) JP6619741B2 (https=)
KR (1) KR102383038B1 (https=)
CN (2) CN106132960B (https=)
AP (1) AP2016009347A0 (https=)
AU (1) AU2015211119B2 (https=)
BR (2) BR112016017344B1 (https=)
CA (1) CA2937967C (https=)
CL (1) CL2016001918A1 (https=)
CR (1) CR20160394A (https=)
CY (2) CY1120348T1 (https=)
DK (2) DK3099684T3 (https=)
EA (1) EA032374B1 (https=)
EC (1) ECSP16070327A (https=)
ES (2) ES2808978T3 (https=)
HK (1) HK1231470A1 (https=)
HR (2) HRP20180813T1 (https=)
HU (2) HUE040274T2 (https=)
IL (1) IL246987B (https=)
LT (2) LT3099684T (https=)
ME (1) ME03800B (https=)
MX (1) MX2016009896A (https=)
MY (1) MY187450A (https=)
NZ (1) NZ722487A (https=)
PE (1) PE20161393A1 (https=)
PH (1) PH12016501493B1 (https=)
PL (2) PL3348556T3 (https=)
PT (2) PT3099684T (https=)
RS (2) RS60547B1 (https=)
SA (1) SA516371579B1 (https=)
SG (1) SG11201606108RA (https=)
SI (2) SI3099684T1 (https=)
SM (2) SMT201800318T1 (https=)
TR (1) TR201809440T4 (https=)
UA (1) UA118209C2 (https=)
WO (1) WO2015116663A1 (https=)
ZA (1) ZA201605246B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN110167937B (zh) * 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138085A1 (en) 2017-01-26 2018-08-02 Ucb Biopharma Sprl Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
JP7283699B2 (ja) * 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2019089640A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
US20250074902A1 (en) 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
CN120265630A (zh) * 2022-11-02 2025-07-04 Ac免疫有限公司 用于诊断tdp-43蛋白质病的新化合物
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
CN121487929A (zh) * 2023-06-25 2026-02-06 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物
CN102803252A (zh) * 2009-06-11 2012-11-28 鲁汶天主教大学研究开发部 用于治疗神经退化性疾病的吲哚酰胺衍生物及其相关化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
DK1697371T3 (da) * 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
EA200801838A1 (ru) * 2006-03-15 2009-02-27 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-kB
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
CA2867175A1 (en) 2012-03-28 2013-10-03 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
ES2661394T3 (es) 2012-07-16 2018-03-28 Neuropore Therapies, Inc. Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CN110167937B (zh) 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803252A (zh) * 2009-06-11 2012-11-28 鲁汶天主教大学研究开发部 用于治疗神经退化性疾病的吲哚酰胺衍生物及其相关化合物
CN102725284A (zh) * 2009-12-16 2012-10-10 神经孔医疗有限公司 适用于治疗共核蛋白病的化合物

Also Published As

Publication number Publication date
PE20161393A1 (es) 2017-01-08
US20180093979A1 (en) 2018-04-05
UA118209C2 (uk) 2018-12-10
AU2015211119A1 (en) 2016-08-11
BR122018001892B1 (pt) 2023-05-02
KR102383038B1 (ko) 2022-04-05
ME03800B (me) 2021-04-20
CA2937967A1 (en) 2015-08-06
MY187450A (en) 2021-09-22
CY1123374T1 (el) 2021-12-31
SG11201606108RA (en) 2016-08-30
HK1231470A1 (zh) 2017-12-22
WO2015116663A8 (en) 2016-09-15
BR112016017344A2 (pt) 2017-10-03
US20190308965A1 (en) 2019-10-10
EP3099684B8 (en) 2018-07-04
ECSP16070327A (es) 2018-05-31
SI3348556T1 (sl) 2020-10-30
PL3348556T3 (pl) 2020-11-02
SI3099684T1 (en) 2018-08-31
PT3099684T (pt) 2018-10-22
HUE040274T2 (hu) 2019-03-28
HRP20201107T8 (hr) 2020-12-11
SMT201800318T1 (it) 2018-07-17
BR112016017344B1 (pt) 2023-05-16
EA032374B1 (ru) 2019-05-31
AU2015211119B2 (en) 2019-05-30
CA2937967C (en) 2022-07-26
KR20160113287A (ko) 2016-09-28
TR201809440T4 (tr) 2018-07-23
PL3099684T3 (pl) 2018-09-28
US20160207912A1 (en) 2016-07-21
ES2808978T8 (es) 2021-03-22
HRP20201107T1 (hr) 2020-10-30
PH12016501493A1 (en) 2017-02-06
SMT202000376T1 (it) 2020-09-10
DK3099684T3 (en) 2018-07-16
DK3348556T3 (da) 2020-08-03
SA516371579B1 (ar) 2019-07-16
HUE050964T2 (hu) 2021-01-28
IL246987B (en) 2021-12-01
CN106132960A (zh) 2016-11-16
MX2016009896A (es) 2017-01-11
PT3348556T (pt) 2020-07-27
IL246987A0 (en) 2016-09-29
NZ722487A (en) 2022-04-29
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
EP3099684A1 (en) 2016-12-07
AU2015211119A8 (en) 2016-12-15
ZA201605246B (en) 2022-05-25
HRP20180813T1 (hr) 2018-07-27
JP2017505779A (ja) 2017-02-23
CY1120348T1 (el) 2019-07-10
LT3348556T (lt) 2020-08-10
AP2016009347A0 (en) 2016-07-31
ES2675301T3 (es) 2018-07-10
CN111039939A (zh) 2020-04-21
ES2808978T3 (es) 2021-03-02
RS60547B1 (sr) 2020-08-31
JP6619741B2 (ja) 2019-12-11
CR20160394A (es) 2016-11-01
CL2016001918A1 (es) 2017-01-13
JP6783900B2 (ja) 2020-11-11
PH12016501493B1 (en) 2017-02-06
CN111039939B (zh) 2023-09-19
RS57533B1 (sr) 2018-10-31
EA201691529A1 (ru) 2017-01-30
LT3099684T (lt) 2018-06-25
US11078196B2 (en) 2021-08-03
JP2019163321A (ja) 2019-09-26
EP3099684B1 (en) 2018-04-04
EP3348556B1 (en) 2020-04-29
WO2015116663A1 (en) 2015-08-06
EP3348556A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
CN106132960B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
JP7100043B2 (ja) タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体
WO2017020010A1 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
CN110191885B (zh) 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
CN112313230A (zh) 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
HK1230613B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺
HK40023286A (en) Heteroaryl amides as inhibitors of protein aggregation
HK1230613A1 (en) Heteroaryl amides as inhibitors of protein aggregation
HK40023286B (zh) 用作蛋白质聚集抑制剂的杂芳基醯胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230613

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20190306

Address after: Brussels

Applicant after: Youshibi Biomedical Co., Ltd.

Address before: American California

Applicant before: NEUROPORE THERAPIES, INC.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant